MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.
What is the ticker symbol for MoonLake Immunotherapeutics? What does MLTX stand for in stocks?
MLTX is the stock ticker symbol of MoonLake Immunotherapeutics. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of MoonLake Immunotherapeutics (MLTX)?
As of Tue Oct 29 2024, market cap of MoonLake Immunotherapeutics is 3.04 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of MLTX stock?
You can check MLTX's fair value in chart for subscribers.
Is MoonLake Immunotherapeutics a good stock to buy?
The fair value guage provides a quick view whether MLTX is over valued or under valued. Whether MoonLake Immunotherapeutics is cheap or expensive depends on the assumptions which impact MoonLake Immunotherapeutics's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MLTX.